Aprocitentan

Aprocitentan
Clinical data
Other names	ACT-132577
ATC code	C02KN01 (WHO) ;
Identifiers
	IUPAC name 5-(4-Bromophenyl)-4-[2-(5-bromopyrimidin-2-yl)oxyethoxy]-6-(sulfamoylamino)pyrimidine;
CAS Number	1103522-45-7;
PubChem CID	25099191;
IUPHAR/BPS	10070;
DrugBank	DB15059;
ChemSpider	25027753;
UNII	MZI81HV01P;
KEGG	D11441;
ChEBI	CHEBI:76609;
ChEMBL	ChEMBL2165326;
Chemical and physical data
Formula	C16H14Br2N6O4S
Molar mass	546.19 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC(=CC=C1C2=C(N=CN=C2OCCOC3=NC=C(C=N3)Br)NS(=O)(=O)N)Br;
	InChI InChI=1S/C16H14Br2N6O4S/c17-11-3-1-10(2-4-11)13-14(24-29(19,25)26)22-9-23-15(13)27-5-6-28-16-20-7-12(18)8-21-16/h1-4,7-9H,5-6H2,(H2,19,25,26)(H,22,23,24); Key:DKULOVKANLVDEA-UHFFFAOYSA-N;

Aprocitentan is an endothelin receptor antagonist active at both endothelin A and endothelin B receptors.^[1] It is developed for resistant hypertension by Idorsia, which sold it to Janssen but purchased the rights back in 2023 for $343 million.^[2]

References

↑ Ojha, Utkarsh; Ruddaraju, Sanjay; Sabapathy, Navukkarasu; Ravindran, Varun; Worapongsatitaya, Pitchaya; Haq, Jeesanul; Mohammed, Raihan; Patel, Vinod (2022). "Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension". American Journal of Cardiovascular Drugs. 22 (3): 271–285. doi:10.1007/s40256-021-00510-9. PMC 8651502. PMID 34878631.
↑ Deswal, Phalguni (6 September 2023). "Idorsia reacquires aprocitentan rights from Janssen for $343m". Pharmaceutical Technology. Retrieved 8 November 2023.
↑ CID 25099191 from PubChem

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.